NASDAQ:SPRO Spero Therapeutics (SPRO) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free SPRO Stock Alerts $1.46 +0.03 (+2.10%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$1.42▼$1.5150-Day Range$1.40▼$1.8052-Week Range$0.99▼$2.00Volume164,757 shsAverage Volume219,213 shsMarket Capitalization$78.68 millionP/E Ratio3.48Dividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Spero Therapeutics alerts: Email Address Spero Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside379.5% Upside$7.00 Price TargetShort InterestHealthy0.95% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.75 out of 5 starsMedical Sector58th out of 913 stocksPharmaceutical Preparations Industry17th out of 420 stocks 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.95% of the outstanding shares of Spero Therapeutics have been sold short.Short Interest Ratio / Days to CoverSpero Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spero Therapeutics has recently decreased by 21.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpero Therapeutics has received a 74.17% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Spero Therapeutics is -0.80. Previous Next 2.7 News and Social Media Coverage News SentimentSpero Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Spero Therapeutics this week, compared to 1 article on an average week.Search Interest4 people have searched for SPRO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.52% of the stock of Spero Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 25.60% of the stock of Spero Therapeutics is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is 3.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.29.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is 3.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 235.73.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Spero Therapeutics Stock (NASDAQ:SPRO)Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More SPRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRO Stock News HeadlinesApril 20, 2024 | americanbankingnews.comSpero Therapeutics (NASDAQ:SPRO) Stock Passes Above Two Hundred Day Moving Average of $1.41March 18, 2024 | markets.businessinsider.comSpero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy RatingApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 17, 2024 | finance.yahoo.comSpero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearMarch 15, 2024 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comSpero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?March 14, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateMarch 14, 2024 | finance.yahoo.comQ4 2023 Spero Therapeutics Inc Earnings CallApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.March 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)March 13, 2024 | benzinga.comRecap: Spero Therapeutics Q4 EarningsMarch 13, 2024 | msn.comSpero Therapeutics GAAP EPS of $0.96 beats by $1.06, revenue of $73.5M beats by $54.87MMarch 13, 2024 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateMarch 12, 2024 | msn.comSpero Therapeutics Q4 2023 Earnings PreviewMarch 6, 2024 | globenewswire.comSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024February 28, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 28, 2024 | markets.businessinsider.comSpero Announces FDA Clearance Of IND Application For SPR206February 28, 2024 | finance.yahoo.comSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 28, 2024 | globenewswire.comSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 26, 2024 | finance.yahoo.comSpero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceFebruary 26, 2024 | globenewswire.comSpero Therapeutics to Present at Cowen's 44th Annual Healthcare ConferenceFebruary 17, 2024 | ca.finance.yahoo.comSPRO Apr 2024 2.000 putFebruary 17, 2024 | ca.finance.yahoo.comSPRO Apr 2024 1.000 callFebruary 10, 2024 | msn.comSpero Therapeutics Announces Chief Legal Officer’s ResignationFebruary 9, 2024 | uk.investing.comSpero Therapeutics Inc (SPRO)February 6, 2024 | finance.yahoo.comSpero Therapeutics Inc CEO Sath Shukla Sells 75,994 SharesJanuary 31, 2024 | finance.yahoo.comSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive SPRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SPRO CUSIPN/A CIK1701108 Websperotherapeutics.com Phone(857) 242-1600FaxN/AEmployees46Year Founded2013Price Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+379.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.42 Trailing P/E Ratio3.48 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.81 million Net Margins21.98% Pretax Margin24.48% Return on Equity38.54% Return on Assets21.56% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio3.53 Sales & Book Value Annual Sales$103.78 million Price / Sales0.76 Cash Flow$0.53 per share Price / Cash Flow2.75 Book Value$2.02 per share Price / Book0.72Miscellaneous Outstanding Shares53,890,000Free Float51,457,000Market Cap$78.68 million OptionableOptionable Beta0.55 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Ankit Mahadevia M.D. (Age 43)MBA, Co-Founder & Chairman of the Board Comp: $1.39MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Comp: $1.12MMr. Timothy Keutzer (Age 56)Chief Operating Officer Comp: $938.57kMs. Esther P. Rajavelu (Age 45)CFO & Chief Business Officer Ted JenkinsVP & Head of Investor RelationsMr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 62)M.D., M.P.H., Chief Medical Officer More ExecutivesKey CompetitorsConnect BiopharmaNASDAQ:CNTBTempest TherapeuticsNASDAQ:TPSTHookipa PharmaNASDAQ:HOOKMarinus PharmaceuticalsNASDAQ:MRNSYS BiopharmaNASDAQ:YSView All CompetitorsInsiders & InstitutionsADAR1 Capital Management LLCBought 1,067,711 shares on 2/14/2024Ownership: 2.015%Kamal HamedSold 39,496 sharesTotal: $50,159.92 ($1.27/share)Sath ShuklaSold 4,163 sharesTotal: $5,411.90 ($1.30/share)Ankit MahadeviaSold 9,040 sharesTotal: $11,390.40 ($1.26/share)Timothy KeutzerSold 1,854 sharesTotal: $2,336.04 ($1.26/share)View All Insider TransactionsView All Institutional Transactions SPRO Stock Analysis - Frequently Asked Questions Should I buy or sell Spero Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRO shares. View SPRO analyst ratings or view top-rated stocks. What is Spero Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Spero Therapeutics' shares. Their SPRO share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 379.5% from the stock's current price. View analysts price targets for SPRO or view top-rated stocks among Wall Street analysts. How have SPRO shares performed in 2024? Spero Therapeutics' stock was trading at $1.47 on January 1st, 2024. Since then, SPRO shares have decreased by 0.7% and is now trading at $1.46. View the best growth stocks for 2024 here. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 513,200 shares, a decrease of 21.5% from the March 31st total of 653,800 shares. Based on an average trading volume of 321,500 shares, the days-to-cover ratio is currently 1.6 days. View Spero Therapeutics' Short Interest. When is Spero Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SPRO earnings forecast. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Wednesday, March, 13th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of ($0.18) by $1.14. The business earned $73.52 million during the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.98% and a trailing twelve-month return on equity of 38.54%. What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO? 27 employees have rated Spero Therapeutics Chief Executive Officer Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among the company's employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), Kadmon (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN). When did Spero Therapeutics IPO? Spero Therapeutics (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. How do I buy shares of Spero Therapeutics? Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
